Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota.

J Nanobiotechnology · 2025 · PMC11881431 · PMID 40038718

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

an increasing trendp < 0.001actually significant

Conversely, NAR and NP-NAR interventions significantly reduced NEFA and VLDL levels ( p < 0.001), with an increasing trend in Apo-B levels (Fig. 1 J-L), and NP-NAR acted significantly better than NAR in lowering hepatic NEFA and VLDL ( p < 0.001).

also in 25,605 other papers

a decreasing trendno p-value reported

1 F), and a decreasing trend in TC and HDL-C (Fig. 1 G, I).

also in 20,364 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.